Kellie Bodeker, MSHS, CCRC, ACRP-PM is proud to announce that she is the first cohort of the THS doctoral program. In addition, she is also the co-first author of a paper reporting the results of our first-in-human clinical trial in glioblastoma multiforme. This work is significant because it adds pharmacological ascorbate (high dose ascorbate) to standard-of-care chemotherapy and radiation therapy to treat a brain tumor. This trial identified the recommended phase 2 dose (87.5 g) and also provided initial insight that the side effects of antineoplastic therapy seem to decrease when participants received the study drug. Lastly, not only did Kellie Bodeker to help design the trial, she was the project manager and also manage the investigational new drug (IND) FDA submission for the drug under investigation.
If you have an account with the University of Iowa please use the following link to read the full publication.